Submission of intimation of approval of amendment in MOA.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shareholders of Astal Laboratories Limited approved an alteration to Clause V of the MOA at an Extraordinary General Meeting held on November 6, 2025. The company's authorised share capital has been increased from Rs. 20 crore to Rs. 50 crore, representing a 2.5x expansion. Correspondingly, the maximum number of equity shares authorised has been raised from 2 crore to 5 crore shares, each with a face value of Rs. 10. The increase in authorised capital gives the board more room to issue new shares in the future, though no actual issuance has been announced yet. The intimation was filed with BSE on November 9, 2025, under SEBI Listing Regulations.
The higher authorised capital ceiling does not immediately dilute existing shareholders, but it signals that the company may be preparing for a future fundraising round or stock split. Investors should watch for any follow-up announcements about a preferential allotment, rights issue, or further capital expansion.